构建人类OATP基质的预测PBPK模型:使用pitavastatin作为例子进行临床药物动力学变异早期评估的战略框架
Xiaomin Liang1, Megan L Koleske1, Jesse Yang1
1Drug Metabolism, Gilead Sciences Inc., 333 Lakeside Dr., Foster City, California, 94404, USA.
The AAPS journal
|January 5, 2024
概括
这项研究提供了一个战略框架,用于预测OATP基质的人类药理动力学 (PK) 概况,药物相互作用和与疾病相关的PK变异. 开发的基于生理学的PK模型准确地预测了皮塔瓦斯塔丁PK,证明了它在早期药物开发中的实用性.
科学领域:
- 药理动力学和药物新陈代谢
- 翻译药理学 翻译药理学
- 计算机化药物发现技术
背景情况:
- 准确预测人类的药理动力学 (PK),药物相互作用 (DDI) 和与疾病相关的PK变异对于候选药物选择至关重要.
- 肝移植体显著复杂化了PK预测,需要先进的建模方法.
- 皮塔瓦斯塔丁作为一个模型基质,用于开发和验证战略框架.
研究的目的:
- 为OATP基质开发和验证一个战略框架,用于预测人类PK概况,DDI和疾病群体中的PK变异.
- 利用基于生理学的PK (PBPK) 建模方法,将体外数据与跨物种推断整合起来.
- 在包括遗传多形态和肝功能障碍在内的场景中评估模型的预测性能.
主要方法:
- 构建和校准一只子PBPK模型,以导出用于体外-体内外推算 (IVIVE) 的缩放因子 (SF).
- 使用皮塔瓦斯塔丁开发和验证人类PBPK模型,结合体外人类参数和校准的SFs.
- 使用经过验证的模型,评估基因多态和肝功能障碍人群中的DDI和PK变异.
主要成果:
- 在PBPK模型中,使用校准的SF (3.45为CLint,active,0.14为CLint,passive,1.17为CLint,bile) 和优化的OATP抑制数据,准确地捕获了皮塔瓦斯塔丁PK配置文件.
- 该模型预测了皮塔瓦斯塔丁PK在人类受试者的变化,基因多态性在观察到AUC的20%以内.
- 该模型在结合基于OATP1B生物标志物的功能性减少时,充分预测了肝功能障碍人群中的PK变化.
结论:
- 开发的战略框架能够准确地预测PK配置文件,并在早期药物开发中对OATP基质的PK变异进行评估.
- PBPK建模方法有效地整合了体外数据和跨物种缩放,用于预测人类PK.
- 这种框架对于预测与DDI,遗传多态和肝功能障碍相关的PK变化是有价值的,有助于药物开发决策.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
40
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
40
Pharmacokinetic Models: Overview
703
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
703
Physiological Pharmacokinetic Models: Assumption with Protein Binding
45
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
45
Pharmacokinetic Models: Comparison and Selection Criterion
74
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
74
Analysis of Population Pharmacokinetic Data
264
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
264
One-Compartment Open Model for IV Bolus Administration: General Considerations
208
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
208


